abstract |
The present invention relates to a compound comprising an EZH2 inhibitor and an E3 ligase binder, and a pharmaceutical composition for preventing or treating EZH2-associated disease and a pharmaceutical composition for selectively degrading protein, each containing the compound as an active ingredient. The compound is capable of selectively degrading EZH2, and thus can be usefully applied for treatment of EZH2-associated disease or cancer, specifically a cancer in which EZH2 is overexpressed. |